MedWatch

Analyst: Duodenoscope study is a ray of sunshine on a cloudy day for Ambu

After a discouraging financial guidance from Ambu, which doesn't provide any forecast for endoscope sales for the next financial year, the only saving grace Søren Løntoft Hansen sees for the medtech company is that it has presented exciting clinical data on a new single-use duodenoscope.

Photo: Sydbank/PR

The big financial picture for Ambu this year had largely already been unveiled, and the focus was thus the medtech company's expectations for the upcoming 2021/2022 financial year when the company released a new report on Wednesday.

The new financial guidance, however, disappoints as projections are under those of both analyst consensus estimates and Senior Analyst at Sydbank Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs